Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Immunome Inc. (IMNM:NASDAQ), powered by AI.
Immunome Inc. is currently trading at $17.91. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Immunome Inc. on Alpha Lenz.
Immunome Inc.'s P/E ratio is -7.4.
“Immunome Inc. trades at a P/E of -7.4 (undervalued) with modest ROE of -52.1%.”
Ask for details →Immunome Inc. is a biotechnology company specializing in highly innovative research and development within the life sciences sector. The primary focus of the company is to advance immunotherapy-based cancer treatments through its proprietary discovery engine that harnesses the immune system's natural capabilities. Immunome’s approach involves leveraging its unique antigen technology to identify novel targets and develop therapeutic antibodies, aimed at enabling the body's immune response to recognize and combat cancer more effectively. This cutting-edge focus places Immunome Inc. squarely at the forefront of the biologics market, with potential applications spanning various oncology therapies. Since its inception, the company has continually explored partnerships with academic institutions and other biotech firms, enhancing collaborative efforts to propel novel findings from the laboratory to clinical trials. Immunome’s efforts contribute significantly to the pharmaceutical and healthcare industries, underscoring the growing importance of targeted therapies and personalized medicine in addressing complex medical challenges. Based in Exton, Pennsylvania, Immunome Inc. represents a key player in translating breakthrough immunological insights into tangible healthcare solutions, emphasizing robust scientific innovation in combating one of the world's most persistent health issues.
“Immunome Inc. trades at a P/E of -7.4 (undervalued) with modest ROE of -52.1%.”
Ask for details →Immunome Inc. (ticker: IMNM) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 155 employees. Market cap is $1.6B.
The current price is $17.91 with a P/E ratio of -7.37x and P/B of 2.47x.
ROE is -52.09% and operating margin is -3228.83%. Annual revenue is $7M.